Acute Heart Failure Management in the USA and Japan: Overview of Practice Patterns and Review of Evidence

Overview

Journal ESC Heart Fail

Date 2018 Jun 23

PMID 29932314

Citations 11

Authors

Toshikazu D Tanaka

Mitsuaki Sawano

Ravi Ramani

Mark Friedman

Shun Kohsaka

Affiliations

Soon will be listed here.

Abstract

Globally, acute heart failure (AHF) remains an ongoing public health issue with its prevalence and mortality increasing in the east and the west. Effective treatment strategies to stabilize AHF are important to alleviate clinical symptoms and to improve clinical outcomes. However, despite the progress in the management of stable and chronic heart failure, no single agent has been proven to play a definitive role in the management of AHF. As a consequence, contemporary treatment strategies for patients with AHF vary greatly by region. This manuscript reviews the medical treatment options for AHF, with an emphasis on the differences between the treatment strategies in the USA and Japan. This information would provide a framework for clinicians to evaluate and manage patients with AHF and highlight the remaining questions to improve clinical outcomes.

Citing Articles

In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial.

Tanaka A, Kida K, Matsue Y, Imai T, Suwa S, Taguchi I Eur Heart J. 2024; 45(42):4482-4493.

PMID: 39215531 PMC: 11544311. DOI: 10.1093/eurheartj/ehae561.

Sacubitril/valsartan in Heart Failure and Beyond-From Molecular Mechanisms to Clinical Relevance.

Nikolic M, Srejovic I, Jovic J, Sretenovic J, Jeremic J, Cekerevac I Rev Cardiovasc Med. 2024; 23(7):238.

PMID: 39076908 PMC: 11266818. DOI: 10.31083/j.rcm2307238.

Novel enhancers of guanylyl cyclase-A activity acting via allosteric modulation.

Andresen H, Perez-Ternero C, Robinson J, Dickey D, Hobbs A, Potter L Br J Pharmacol. 2023; 180(24):3254-3270.

PMID: 37522273 PMC: 10952227. DOI: 10.1111/bph.16203.

Natriuretic Peptides: It Is Time for Guided Therapeutic Strategies Based on Their Molecular Mechanisms.

Gallo G, Rubattu S, Autore C, Volpe M Int J Mol Sci. 2023; 24(6).

PMID: 36982204 PMC: 10049669. DOI: 10.3390/ijms24065131.

Diagnostic utility of lung echography for congestive heart failure performed by junior resident doctors.

Nagaharu K, Tsumura N, Itoh T, Murata T J Gen Fam Med. 2022; 23(6):401-406.

PMID: 36349208 PMC: 9634130. DOI: 10.1002/jgf2.575.

References

Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K . Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J. 2014; 78(4):844-52. View

Packer M, Carver J, Rodeheffer R, Ivanhoe R, DiBianco R, Zeldis S . Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991; 325(21):1468-75. DOI: 10.1056/NEJM199111213252103. View

Rosenberg J, Gustafsson F, Galatius S, Hildebrandt P . Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther. 2005; 19(4):301-6. DOI: 10.1007/s10557-005-3350-2. View

Gheorghiade M, Gattis W, OConnor C, Adams Jr K, Elkayam U, Barbagelata A . Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004; 291(16):1963-71. DOI: 10.1001/jama.291.16.1963. View

Sasayama S, Asanoi H, Kihara Y, Yokawa S, Terada Y, Yoshida S . Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. Heart Vessels. 1994; 9(3):113-20. DOI: 10.1007/BF01745236. View

Mebazaa A, Gheorghiade M, Pina I, Harjola V, Hollenberg S, Follath F . Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008; 36(1 Suppl):S129-39. DOI: 10.1097/01.CCM.0000296274.51933.4C. View

Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K . Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol. 2013; 53(12):1277-85. PMC: 4258069. DOI: 10.1002/jcph.197. View

Nomura F, Kurobe N, Mori Y, Hikita A, Kawai M, Suwa M . Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated.... Circ J. 2008; 72(11):1777-86. DOI: 10.1253/circj.cj-07-0760. View

Konstam M, Kiernan M, Chandler A, Dhingra R, Mody F, Eisen H . Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload. J Am Coll Cardiol. 2017; 69(11):1409-1419. DOI: 10.1016/j.jacc.2016.12.035. View

10.

Dohi K, Ito M . Novel diuretic strategies for the treatment of heart failure in Japan. Circ J. 2014; 78(8):1816-23. DOI: 10.1253/circj.cj-14-0592. View

11.

Yancy C, Lopatin M, Stevenson L, De Marco T, Fonarow G . Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006; 47(1):76-84. DOI: 10.1016/j.jacc.2005.09.022. View

12.

Gheorghiade M, Follath F, Ponikowski P, Barsuk J, Blair J, Cleland J . Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care.... Eur J Heart Fail. 2010; 12(5):423-33. DOI: 10.1093/eurjhf/hfq045. View

13.

Cohn J, Goldstein S, GREENBERG B, Lorell B, Bourge R, Jaski B . A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998; 339(25):1810-6. DOI: 10.1056/NEJM199812173392503. View

14.

Pang P, Konstam M, Krasa H, Swedberg K, Zannad F, Blair J . Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J. 2009; 30(18):2233-40. PMC: 2742783. DOI: 10.1093/eurheartj/ehp253. View

15.

Gorodeski E, Chu E, Reese J, Shishehbor M, Hsich E, Starling R . Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. Circ Heart Fail. 2009; 2(4):320-4. DOI: 10.1161/CIRCHEARTFAILURE.108.839076. View

16.

Breidthardt T, Noveanu M, Potocki M, Reichlin T, Egli P, Hartwiger S . Impact of a high-dose nitrate strategy on cardiac stress in acute heart failure: a pilot study. J Intern Med. 2009; 267(3):322-30. DOI: 10.1111/j.1365-2796.2009.02146.x. View

17.

Matsue Y, Kagiyama N, Yoshida K, Kume T, Okura H, Suzuki M . Carperitide Is Associated With Increased In-Hospital Mortality in Acute Heart Failure: A Propensity Score-Matched Analysis. J Card Fail. 2015; 21(11):859-64. DOI: 10.1016/j.cardfail.2015.05.007. View

18.

Gheorghiade M, Konstam M, Burnett Jr J, Grinfeld L, Maggioni A, Swedberg K . Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007; 297(12):1332-43. DOI: 10.1001/jama.297.12.1332. View

19.

Cuffe M, Califf R, Adams Jr K, Benza R, Bourge R, Colucci W . Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002; 287(12):1541-7. DOI: 10.1001/jama.287.12.1541. View

20.

Sommers B, Gawande A, Baicker K . Health Insurance Coverage and Health - What the Recent Evidence Tells Us. N Engl J Med. 2017; 377(6):586-593. DOI: 10.1056/NEJMsb1706645. View